Stanford University
Showing 51-60 of 70 Results
-
Andrew Rezvani, M.D.
Associate Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Current Research and Scholarly InterestsClinical research in allogeneic hematopoietic cell transplantation
-
Parveen Shiraz, MD
Instructor, Medicine - Blood & Marrow Transplantation
Current Research and Scholarly InterestsI am a physician-scientist in the Division of Blood and Marrow Transplantation-Cell Therapy (BMT-CT) at Stanford University. The focus of my laboratory research is the exploration of safe and more accessible forms of cell therapy for myeloid malignancies. We are studying multi-antigen targeting antibodies and engineered Natural Killer cells for myeloid malignancies.
-
Judith Shizuru
Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Current Research and Scholarly InterestsTransplantation of defined populations of allogeneic hematopoietic cells. Specifically, the way in which hematopoietic cell grafts alter antigen specific immune responses to allo-, auto- and viral antigens. The cellular and molecular basis of resistance to engraftment of allogeneic hematopoietic stem cells.
-
Surbhi Sidana, MD
Associate Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
BioDr. Surbhi Sidana is an Associate Professor of Medicine at Stanford University and specializes in the treatment of multiple myeloma and related disorders. She leads the Myeloma CAR-T/Immunotherapy program at Stanford.
Dr Sidana grew up in Delhi, India. She completed her Internal Medicine Residency at Cleveland Clinic in Cleveland, Ohio, followed by Hematology/Oncology fellowship at Mayo Clinic in Rochester, MN. Following this, she completed an Advanced Hematology Fellowship in Myeloma, Amyloidosis and Related Disorders at Mayo Clinic in Rochester, MN before joining Stanford University as a faculty member in 2019, where she has led the development of the myeloma CAR-T and bispecific antibody program.
Dr Sidana has an active, broad research portfolio that includes clinical trials of novel therapies in myeloma and related disorders, translational research, epidemiologic and patient reported outcome studies. She has a special focus on research with immunotherapies such as CAR-T cell therapy and bispecific antibodies. She has published over 100 research manuscripts. Dr Sidana is the Leader of the Myeloma Disease Focused Group and the Associate Director for Clinical Research in the BMT and Cell Therapy Division at Stanford University. She also co-leads a multi-institutional collaboration on real world outcomes with immunotherapies in myeloma.
Dr Sidana is actively involved in and holds leadership positions in national and international professional societies. She is the Chair of the American Society of Hematology Committee on Communications, and Co-Chairs the Quality-of-Life Committee of the International Myeloma Working Group. She is a member of the SWOG Myeloma Committee and BMT CTN Myeloma Intergroup, where she works with colleagues across the nation to develop innovative and practice changing trials focused on multiple myeloma .
